Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens

Irene G M van Valkengoed¹, Maarten J Postma², Servaas A Morré³, Adriaan J C van den Brule³, Chris J L M Meijer³, Lex M Bouter¹, A Joan P Boeke¹

¹ Institute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam, Netherlands
² Groningen University Institute for Drug Exploration, Groningen, Netherlands
³ University Hospital Vrije Universiteit, Department of Pathology, Section of Molecular Pathology, Amsterdam, Netherlands

Correspondence to:
Dr A J P Boeke, Institute for Research in Extramural Medicine, Vrije Universiteit, Van der Boechorststraat 7, 1081 BT Amsterdam, Netherlands ajp.boeke.emgo{at}med.vu.nl

Objectives: To evaluate the cost effectiveness of a systematic screening programme for asymptomatic Chlamydia trachomatis infections in a female inner city population. To determine the sensitivity of the cost effectiveness analysis to variation in the probability of developing sequelae.

Methods: A decision tree was constructed to evaluate health effects of the programme, such as averted sequelae of chlamydial infection. Cost effectiveness from a societal perspective was estimated for screening by means of a ligase chain reaction on mailed, home obtained urine specimens, in a population with a C trachomatis test prevalence of 2.9%. An extensive sensitivity analysis was performed for the probability of sequelae, the percentage of preventable pelvic inflammatory disease (PID), and the discount rate.

Results: The estimated net cost of curing one woman, aged 15–40 years, of a C trachomatis infection is US$1210. To prevent one major outcome (PID, tubal factor infertility, ectopic pregnancy, chronic pelvic pain, or neonatal pneumonia), 479 women would have to be screened. The net cost of preventing one major outcome is $15 800. Changing the probability of PID after chlamydial infection from 5% to 25% decreases the net cost per major outcome averted from $28 300 to $6380, a reduction of 78%. Results were less sensitive to variations in estimates for other sequelae. The breakeven prevalence of the programme ranges from 6.4% for the scenario with all probabilities for complications set at the maximum value to a prevalence of 100% for probabilities set at the minimum value.

Conclusions: Systematic screening of all women aged 15–40 years for asymptomatic C trachomatis infections is not cost effective. Although the results of the analyses are sensitive to variation in the assumptions, the costs exceed the benefits, even in the most optimistic scenario.

Key Words: cost effectiveness analysis; Chlamydia trachomatis; screening

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Barham, L, Lewis, D, Latimer, N (2007). One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations. Sex. Transm. Infect. 83: 441-446 [Abstract] [Full Text]  
• Robinson, S., Roberts, T., Barton, P., Bryan, S., Macleod, J., McCarthy, A., Egger, M., Sanford, E., Low, N., for the Chlamydia Screening Studies (ClaSS) Projec, (2007). Healthcare and patient costs of a proactive chlamydia screening programme: the Chlamydia Screening Studies project. Sex. Transm. Infect. 83: 276-281 [Abstract] [Full Text]  
• Michel, C.-E. C., Sonnex, C., Carne, C. A., White, J. A., Magbanua, J. P. V., Nadala, E. C. B. Jr., Lee, H. H. (2007). Chlamydia trachomatis Load at Matched Anatomic Sites: Implications for Screening Strategies. J. Clin. Microbiol. 45: 1395-1402 [Abstract] [Full Text]  
• Peeling, R W (2006). Testing for sexually transmitted infections: a brave new world?. Sex. Transm. Infect. 82: 425-430 [Full Text]  
• van Hamont, D., Nissen, L.H.C., Siebers, A.G., Hendriks, J.C.M., Melchers, W.J.G., Kremer, J.A.M., Massuger, L.F.A.G. (2006). Abnormal cervical cytology in women eligible for IVF. Hum Reprod 21: 2359-2363 [Abstract] [Full Text]  
• Roberts, T E, Robinson, S, Barton, P, Bryan, S, Low, N, for the Chlamydia Screening Studies (ClaSS) Group, (2006). Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling.. Sex. Transm. Infect. 82: 193-200 [Abstract] [Full Text]  
• Senok, A., Wilson, P., Reid, M., Scoular, A., Craig, N., McConnachie, A., Fitzpatrick, B., MacDonald, A. (2005). Can we evaluate population screening strategies in UK general practice? A pilot randomised controlled trial comparing postal and opportunistic screening for genital chlamydial infection. J. Epidemiol. Community Health 59: 198-204 [Abstract] [Full Text]  
• van Bergen, J, Gotz, H M, Richardus, J H, Hoebe, C J P A, Broer, J, Coenen, A J T, for the PILOT CT study group, (2005). Prevalence of urogenital Chlamydia trachomatis increases significantly with level of urbanisation and suggests targeted screening approaches: results from the first national population based study in the Netherlands. Sex. Transm. Infect. 81: 17-23 [Abstract] [Full Text]  
• Mak, R P, Van Renterghem, L, Traen, A (2005). Chlamydia trachomatis in female sex workers in Belgium: 1998-2003. Sex. Transm. Infect. 81: 89-90 [Abstract] [Full Text]  
• van Valkengoed, I. G., Morre, S. A, van den Brule, A. J., Meijer, C. J., Bouter, L. M, Boeke, A J. P (2004). Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses. Int J Epidemiol 33: 416-425 [Abstract] [Full Text]  
• Van Der Pol, B., Williams, J. A., Smith, N. J., Batteiger, B. E., Cullen, A. P., Erdman, H., Edens, T., Davis, K., Salim-Hammad, H., Chou, V. W., Scearce, L., Blutman, J., Payne, W. J. (2002). Evaluation of the Digene Hybrid Capture II Assay with the Rapid Capture System for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J. Clin. Microbiol. 40: 3558-3564 [Abstract] [Full Text]  
• Low, N., Egger, M. (2002). What should we do about screening for genital chlamydia?. Int J Epidemiol 31: 891-893 [Full Text]  
• Postma, M J, Welte, R, van den Hoek, J., Morre, S A (2002). Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches. Sex. Transm. Infect. 78: 73-74 [Full Text]  
• Morre, S A, Welte, R, Postma, M J (2002). Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing. Sex. Transm. Infect. 78: 74-75 [Full Text]  
• Gupta, M, Hernon, M, Gokhale, R, Ghosh, A K (2002). Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women. Sex. Transm. Infect. 78 : 76-76 [Full Text]